Bristol-Myers Squibb Buys Mirati Therapeutics to Boost Cancer Drug Portfolio
Bristol-Myers Squibb agreed to pay up to $5.8 billion for Mirati Therapeutics to boost its portfolio of cancer-fighting treatments.
( 1
min )